Fujirebio

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

Fujirebio is a Japanese multinational in vitro diagnostics (IVD) company, founded in 1950 and headquartered in Tokyo, Japan. The company develops, manufactures, and markets IVD testing products — including reagents, instruments, and software — for clinical diagnostics and research use. Fujirebio operates offices in Asia, Europe, and the United States, and maintains a broad international distribution network, with manufacturing facilities in Japan, Europe, and the United States. The company employs more than 1,400 people globally. Fujirebio operates an open business model in which it develops novel biomarkers and diagnostic content, validates them using its own fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform, and distributes them globally through partnerships and a Contract Development and Manufacturing Organization (CDMO) model — providing development, manufacturing, and regulatory services to third-party diagnostic companies. The company’s principal areas of expertise include oncology, infectious diseases, and neurological disorders. In May 2025, Fujirebio received FDA 510(k) clearance for the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based IVD test to aid in identifying amyloid pathology associated with Alzheimer’s disease. In 2022, Fujirebio acquired ADx NeuroSciences, a Belgian biotech company specializing in neurological biomarker research, for €40 million. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc. (Tokyo Stock Exchange: TYO 4544), which also includes SRL Inc., the largest commercial clinical laboratory in Japan.